Shuyan Chen's Contact Details

Shuyan Chen's Company Details

CellMosaic, Inc.

Woburn, MA, US • 5 - 9 Employees
BioTech/Drugs

CellMosaic®, Inc. is an innovator and leader in bioconjugation and crosslinking technologies. The company was established in 2008 by Dr. Huang, a technological entrepreneur with profound interest and experience in the conjugation field. Since 2008, CellMosaic® has spent a lot of research effort on developing advanced conjugation processes that involve controlled, site-specific, or single labeling methods. These processes can generate single ratio conjugates with greater than 90% purity. We have built a successful custom conjugation service business based on these processes and delivered more than 150 projects and 100 unique conjugates (as of Apr. 2017) for our customers covering a variety of compounds, including proteins, antibodies, peptides, oligos, enzymes, and chemotherapeutic agents. Recently, CellMosaic started to commercialize personalized™ conjugation kits (PerKit™) based on these conjugation processes. Customers can use these kits in house to prepare conjugates with similar high quality as we do at CellMosaic. Over the years, CellMosaic® has also pioneered the concept of utilizing sugar alcohol (SA) monomers to chemically assemble a new type of crosslinking reagents and polymer carriers, called AqueaTether™ (AqT™), for conjugation and drug delivery. Several other key technologies have also been developed at CellMosaic®, including oxLink™ and sxLink™ technologies for studying protein–protein interactions, and NeIon™ technologies for detecting and quantitating trace amounts of analytes of interest by Mass Spectrometry. Currently, we are developing products using these technologies for R&D usage. One of the main goals of developing AqT™ linkers and polymers is for drug conjugation and delivery. Please visit www.aqttherapeutics.com to learn more about these applications. Customers who wish to develop their own proprietary therapeutics based on AqT linkers and polymers are encouraged to contact us for how to access these technologies.